ALVO vs TEVA vs RDY Stock Comparison

Alvotech, Teva Pharmaceutical Industries and Dr Reddys Laboratories Prices as of Nov 13, 2026 Peers: Industry group
ALVO Alvotech
$4.19 -19.0% 1M -24.1% 1Y
Market cap
$1.27B
P/E
–
Revenue (TTM)
-$131.44M
Div. yield
–
Generic Drugs Healthcare
2 wins

Head to Head

11 decided of 12

Teva Pharmaceutical Industries leads on 5 of the 12 questions below (Teva Pharmaceutical Industries 5, Dr Reddys Laboratories 4, Alvotech 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionALVOTEVARDYLeader
Larger companyMarket capitalisation $1.27B $49.74B $12.24B TEVA
Cheaper on earningsLower P/E, profitable companies only -41.2x 98.3x 33.7x RDY
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 22.7x 30.7x TEVA
Faster revenue growthRevenue growth, trailing twelve months -137.5% +2.7% -10.5% TEVA
More profitableNet margin, trailing twelve months — 2.9% 10.2% RDY
Better return on capitalReturn on invested capital 8.2% 5.9% 5.6% ALVO
Less leveragedLower net debt / EBITDA 4.6x 5.2x 1.2x RDY
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -24.1% +74.4% +6.3% TEVA
Better 5-year returnAnnualised price return, 5 years -15.8%/yr +36.2%/yr +2.5%/yr TEVA
Less volatileAnnualised volatility, 1 year 70.5% 33.4% 26.6% RDY
Higher overall scoreMean of the five percentile scores vs peers 66/100 62/100 57/100 ALVO

Percentile Scorecard

ALVOTEVARDY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisALVOTEVARDY
Valuation 94 #41 of 660 82 #120 of 660 90 #66 of 660
Growth 79 #132 of 619 68 #201 of 619 12 #546 of 619
Profitability 71 #172 of 595 86 #87 of 595 85 #92 of 595
Financial Health 22 #536 of 683 11 #608 of 683 41 #405 of 683
Shareholder Returns – – 60 #186 of 459
Overall 66 62 57
  • ALVO ranked among 695 companies in Pharmaceuticals and Biotechnology
  • TEVA ranked among 695 companies in Pharmaceuticals and Biotechnology
  • RDY ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodALVOTEVARDYSPY
1 month -19.0%+9.3%+15.7% -2.0%
3 months +3.5%+21.1%+20.1% -2.8%
6 months +26.6%+29.9%+8.4% +2.0%
Year to date -18.3%+42.7%+5.1% +10.6%
1 year -24.1%+74.4%+6.3% +12.2%
3 years -53.4%+399.9%+13.0% +68.1%
3 years, per year -22.5%+71.0%+4.2% +18.9%
5 years -57.7%+368.3%+13.4% +61.4%
5 years, per year -15.8%+36.2%+2.5% +10.1%
10 years —+9.6%+52.0% +248.5%
10 years, per year —+0.9%+4.3% +13.3%

Risk

MeasureALVOTEVARDYSPY
Volatility, 1Y 70.5%33.4%26.6% 13.6%
Downside volatility, 1Y 65.0%27.5%27.6% 13.9%
Beta vs S&P 500, 1Y 0.840.590.34 1.00
Return / volatility, 1Y -0.342.230.24 0.90
Max drawdown, 5Y -82.6%-43.7%-32.3% -25.4%
From 52-week high -31.9%0.0%-4.1% -3.2%
52-week high $6.15$44.54$15.38 $779.14
52-week low $3.00$24.21$11.40 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleALVOTEVARDY
P/E now vs peer median -39.2xmedian 17.0x 102.6xmedian 17.0x 33.8xmedian 17.0x
P/S now vs peer median -9.9xmedian 8.4x 3.0xmedian 8.4x 3.5xmedian 8.4x
EV/EBITDA now vs peer median 9.5xmedian 14.6x 26.7xmedian 14.6x 24.4xmedian 14.6x
P/FCF now vs peer median -10.7xmedian 19.0x 42.0xmedian 19.0x 882.1xmedian 19.0x
P/B now vs peer median -4.6xmedian 2.0x 6.5xmedian 2.0x 3.0xmedian 2.0x
PEG now vs peer median —median 0.43 3.39median 0.43 -1.59median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsALVOTEVARDY
Revenue -$131.44M $17.23B $174.86B
Gross profit -$270.71M $9.22B $86.67B
Operating income $142.52M $1.44B $16.77B
Net income $52.16M $508.00M $275.07M
Free cash flow -$122.64M $1.24B $400.42M
R&D $92.89M $1.76B $12.52B
EPS (diluted) $-0.11 $0.43 $0.44
Cash & equivalents $172.36M $4.09B $138.41M
Total debt $1.40B $16.72B $783.69M
Shares (diluted) 291.34M 1.18B 833.33M
Enterprise value $723.45M $34.70B $11.58B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricALVOTEVARDY
P/E -39.2x 102.6x 33.8x
P/FCF -10.7x 42.0x 882.1x
P/Operating cash flow -22.5x 29.4x 36.2x
P/S -9.9x 3.0x 3.5x
P/B -4.6x 6.5x 3.0x
P/Tangible book -2.8x 11.1x 4.1x
EV/EBITDA 9.5x 26.7x 24.4x
EV/EBIT 17.8x 45.0x 37.2x
EV/Revenue -19.3x 3.7x 3.6x
EV/FCF -20.6x 52.3x 926.1x
EV/Operating cash flow -43.5x 36.5x 38.0x
PEG (3Y EPS CAGR) – 3.39 -1.59

Growth

14 metrics
MetricALVOTEVARDY
Revenue growth (1Y) -137.5% 2.7% -10.5%
Revenue CAGR (3Y) – 4.1% 3.2%
Gross profit growth (1Y) -383.2% 9.7% -21.5%
Gross profit CAGR (3Y) – 9.6% -2.3%
Operating income growth (1Y) 166.0% -21.5% -58.2%
Operating income CAGR (3Y) – 46.4% -24.1%
Net income growth (1Y) 122.5% -23.3% -55.9%
Net income CAGR (3Y) – 30.3% -21.5%
EPS growth (1Y) 87.7% -30.1% -54.1%
EPS CAGR (3Y) – 30.2% -21.3%
Operating cash flow growth (1Y) 75.4% 66.0% -39.6%
Operating cash flow CAGR (3Y) – 15.2% -27.1%
Free cash flow growth (1Y) 52.6% 113.8% -98.4%
Free cash flow CAGR (3Y) – 26.7% -73.6%

Profitability

14 metrics
MetricALVOTEVARDY
Gross margin – 53.5% 49.5%
EBITDA margin – 14.0% 14.9%
Operating margin – 8.3% 9.7%
Pretax margin – 2.1% 10.7%
Net margin – 2.9% 10.2%
FCF margin – 7.2% 0.4%
Operating cash flow margin 44.3% 10.3% 9.5%
Return on equity – 6.5% 7.4%
Return on assets -1.9% 1.3% 5.0%
Return on invested capital 8.2% 5.9% 5.6%
Return on capital employed 11.0% 5.9% 7.9%
Asset turnover -0.1x 0.4x 0.6x
Cash conversion (OCF / net income) -1.1x 3.5x 1.1x
Stock comp / revenue -5.0% 1.0% 0.1%

Financial Health

11 metrics
MetricALVOTEVARDY
Debt / assets 86.4% 41.8% 12.6%
Debt / equity -4.9x 2.1x 0.2x
Net debt / EBITDA 4.6x 5.2x 1.2x
Debt / FCF -11.4x 13.5x 53.9x
Liabilities / assets 117.6% 80.1% 32.2%
Equity / assets -17.6% 19.9% 67.8%
Interest coverage 44.7x – 7.2x
Current ratio 1.9x 0.9x 1.9x
Quick ratio 1.4x 0.5x 0.7x
Cash ratio 0.6x 0.3x 0.1x
Altman Z-score -1.39 1.02 5.79

Shareholder Returns

7 metrics
MetricALVOTEVARDY
Dividend yield – – 0.5%
Net buyback yield – – -0.1%
Shareholder yield – 0.0% 0.5%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusALVOTEVARDY
Forward P/E – 22.7xFY2026 30.7xFY2026
EPS, next fiscal year $-0.04FY2026 $1.96FY2026 $0.48FY2026
EPS growth, next FY – -33.1%FY2026 -11.1%FY2026
EPS growth, the year after – +65.3% +20.8%
Revenue, next fiscal year $555.88MFY2026 $15.89BFY2026 $3.84BFY2026
Revenue growth, next FY -6.3%FY2026 -8.0%FY2026 +9.3%FY2026
Revenue growth, the year after +23.4% +16.5% +3.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersALVOTEVARDY
Held by institutions 14.7% 62.7% 15.1%
Institutions holding 72 672 239
Change in shares held, QoQ +152.4% +8.6% +4.3%
Institutions buying 44 359 108
Institutions selling 17 192 97
Buyers to sellers 2.59 1.87 1.11

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ALVOTEVARDY
ALVO 1.00 0.16 0.13
TEVA 0.16 1.00 0.28
RDY 0.13 0.28 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ALVO, TEVA and RDY?

Teva Pharmaceutical Industries (TEVA) is the largest by market capitalisation: Alvotech (ALVO) $1.27B, Teva Pharmaceutical Industries (TEVA) $49.74B, Dr Reddys Laboratories (RDY) $12.24B.

Which stock is cheaper, ALVO, TEVA and RDY?

Dr Reddys Laboratories (RDY) trades on the lowest price-to-earnings ratio (Alvotech (ALVO) -41.2x, Teva Pharmaceutical Industries (TEVA) 98.3x, Dr Reddys Laboratories (RDY) 33.7x). On next year's consensus earnings, Teva Pharmaceutical Industries (TEVA) is cheapest (Teva Pharmaceutical Industries (TEVA) 22.7x, Dr Reddys Laboratories (RDY) 30.7x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Teva Pharmaceutical Industries (TEVA) grew revenue fastest over the trailing twelve months: Alvotech (ALVO) -137.5%, Teva Pharmaceutical Industries (TEVA) +2.7%, Dr Reddys Laboratories (RDY) -10.5%.

Which company is more profitable?

Dr Reddys Laboratories (RDY) has the highest net margin (Teva Pharmaceutical Industries (TEVA) 2.9%, Dr Reddys Laboratories (RDY) 10.2%). On return on invested capital, Alvotech (ALVO) leads (Alvotech (ALVO) 8.2%, Teva Pharmaceutical Industries (TEVA) 5.9%, Dr Reddys Laboratories (RDY) 5.6%).

Which stock has performed better?

Over the past year Teva Pharmaceutical Industries (TEVA) returned the most: Alvotech (ALVO) -24.1%, Teva Pharmaceutical Industries (TEVA) +74.4%, Dr Reddys Laboratories (RDY) +6.3%. Over five years, Teva Pharmaceutical Industries (TEVA) compounded fastest (Alvotech (ALVO) -15.8%/yr, Teva Pharmaceutical Industries (TEVA) +36.2%/yr, Dr Reddys Laboratories (RDY) +2.5%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Dr Reddys Laboratories (RDY) has been the steadiest (Alvotech (ALVO) 70.5%, Teva Pharmaceutical Industries (TEVA) 33.4%, Dr Reddys Laboratories (RDY) 26.6%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ALVO, TEVA and RDY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Teva Pharmaceutical Industries (TEVA) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.